A/Prof Matthew Wakefield
Principal Research Fellow
Department of Obstetrics, Gynaecology and Newborn Health
154 Scholarly works
3 Projects
HIGHLIGHTS
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12020
Research Contracts
Sal Contribution - Matthew Wakefield 20/21 - (Wehi)
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2018
Journal article
DNA repair processes are critical mediators of p53-dependent tumor suppression letter
DOI: 10.1038/s41591-018-0043-52017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192016
Conference Proceedings
Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer
DOI: 10.1016/S0959-8049(16)32627-22015
Journal article
AmpliVar: Mutation detection in high-throughput sequence from amplicon-based libraries
DOI: 10.1002/humu.22763
RECENT SCHOLARLY WORKS
2026
Journal article
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
DOI: 10.1186/s13046-025-03629-82026
Journal article
CountESS: a flexible, graphical pipeline tool for deep mutational scanning analysis.
DOI: 10.64898/2026.04.27.7212302026
Journal article
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
DOI: 10.1038/s41416-026-03535-62025
Journal article
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays
DOI: 10.1186/s13059-025-03476-y2025
Journal article
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
DOI: 10.1038/s41467-025-64130-62025
Other
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
DOI: 10.1158/1078-0432.307063352025
Other
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
DOI: 10.1158/1078-0432.307063472025
Other
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
DOI: 10.1158/1078-0432.30706368